相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patterns of Response and Progression in Patients With BRAF-Mutant Melanoma Metastatic to the Brain Who Were Treated With Dabrafenib
Mary W. F. Azer et al.
CANCER (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Melissa A. Wilson et al.
CLINICAL CANCER RESEARCH (2014)
Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics
Vito W. Rebecca et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-Expressing Melanoma
Edward J. Hartsough et al.
MOLECULAR CANCER RESEARCH (2014)
Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Jaime Acquaviva et al.
MOLECULAR CANCER THERAPEUTICS (2014)
MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Jyoti Asundi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Junfeng Xia et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas et al.
LANCET ONCOLOGY (2014)
Copper is required for oncogenic BRAF signalling and tumorigenesis
Donita C. Brady et al.
NATURE (2014)
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
Vito W. Rebecca et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
Alexander M. Menzies et al.
PLOS ONE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
BRAF in Melanoma: Current Strategies and Future Directions
April K. S. Salama et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
Federica Catalanotti et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2013)
BRAF inhibitor activity in V600R metastatic melanoma
Oliver Klein et al.
EUROPEAN JOURNAL OF CANCER (2013)
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Victoria Marsh Durban et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma
Christy C. Ong et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
H. Eirik Haarberg et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert et al.
LANCET ONCOLOGY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Thomas Botton et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
Xinqi Wu et al.
PLOS ONE (2013)
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Elucidating Distinct Roles for NF1 in Melanomagenesis
Ophelia Maertens et al.
CANCER DISCOVERY (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Jessie Villanueva et al.
CELL REPORTS (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2012)
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Kim H. T. Paraiso et al.
CLINICAL CANCER RESEARCH (2012)
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Yingjun Su et al.
CLINICAL CANCER RESEARCH (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor et al.
CLINICAL CANCER RESEARCH (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
Christine M. Lovly et al.
PLOS ONE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Kathryn Tworkoski et al.
MOLECULAR CANCER RESEARCH (2011)
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
Amelie Marquette et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Bianca Devitt et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
Hazem El-Osta et al.
PLOS ONE (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Bevacizumab and Everolimus in the Treatment of Patients With Metastatic Melanoma
John D. Hainsworth et al.
CANCER (2010)
A Mouse Model of Melanoma Driven by Oncogenic KRAS
Carla Milagre et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
P. J. Mishra et al.
ONCOGENE (2010)
BRAF Signaling and Targeted Therapies in Melanoma
Nathalie Dhomen et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
Malihe Eskandarpour et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
SnapShot: Ras signaling
Megan Cully et al.
CELL (2008)
Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement
Victoria Sanz-Moreno et al.
CELL (2008)
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
Panagiotis A. Konstantinopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model
Barbara Bedogni et al.
MOLECULAR CANCER THERAPEUTICS (2006)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
OM Grbovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
SD Dias et al.
CANCER RESEARCH (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
